Pamela Taulbee

Senior writer, health care, The Deal (Washington, D.C.)

Recent Articles By The Author

Pfizer Ponies Up to Develop Long-acting Growth Hormone

Pfizer Ponies Up to Develop Long-acting Growth Hormone

Opko gains $295 million up front for global license to develop, market long-acting HGH.

Third Point's Daniel Loeb Tells Amgen it's Time to Break up

Third Point's Daniel Loeb Tells Amgen it's Time to Break up

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.

Changing hospital dynamic leads Becton Dickinson to buy CareFusion

Changing hospital dynamic leads Becton Dickinson to buy CareFusion

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.

Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.

Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.